Patent ID: 8133900

Claim:
A method for inhibiting JAK2 kinase activity in a subject wherein the subject has rheumatoid arthritis comprising administering to the subject with rheumatoid arthritis a therapeutically effective amount of at least one compound represented by structure (A): wherein: X is selected from the group consisting of a bond, O, and CH 2 ; Y is selected from the group consisting of a bond or NR 9 ; or X and Y taken together is a bond; each R 9 is independently selected from H and C 1 -C 6 alkyl; each of R 1 and R 2 is independently selected from H and C 1 -C 6 alkyl optionally substituted by halogen, amino or hydroxyl; each of p, q, and n is independently selected from 0, 1, 2, 3, 4, 5, and 6; G 0 is N or CH, wherein when G 0 is N, each of R 3 and R 4 , taken together with G 0 , form a heterocyclic ring, wherein the formed heterocyclic ring is optionally substituted by one or two substitutents each independently selected from the group consisting of halogen, C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, hydroxyl, or carboxyl, and and wherein when G 0 =CH, then R 3 and R 4 , taken together with G 0 , form a heterocyclic ring wherein the formed heterocyclic ring is optionally substituted by one or two substitutents each independently selected from the group consisting of halogen, C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, hydroxyl, or carboxyl; G is CR 6′ where each R 6′ is independent of each other group R 6′ ; R 6′ is selected from the group consisting of H, halogen, C(O)—O-alkyl, alkyl, alkoxy, and haloalkyl or R 6′ is a bond when bonded to X; A is NR 9 ; R 5 is methyl; wherein each of R 6 , R 7 , R 8 is independently selected for each occurrence from the group consisting of H, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, SO 2 H, SO 2 (C 1 -C 6 alkyl), SO 2 -heterocycle, SO 2 -cycloalkyl, —SO 2 NH(C 1 -C 6 alkyl), SO 2 N(C 1 -C 6 alkyl)(C 1 -C 6 alkyl), SO 2 NH(cycloalkyl), SO 2 NH-heterocycle, SO 2 NH(branched alkyl), NO 2 , CN, CONH 2 , CO—(C 1 -C 6 alkyl), COOH, COO—(C 1 -C 6 alkyl), and NHCO—(C 1 -C 6 alkyl), or R 6 and R 7 taken together, or R 7 and R 8 taken together, or R 6 and R 8 taken together form a moiety independently selected from the group consisting of —CH═CH—CH═CH— and —O—(CH 2 ) n —O—; G 1 is CH; and G 2 is CR 7 , with each group R 7 being independent of every other group R 7 ; or a pharmaceutically acceptable salt thereof.